RSS   Newsletter   Contact   Advertise with us

CMA says Illumina-Pacific Biosciences deal could hurt competition

Christian Fernsby ▼ | June 18, 2019
Britain’s competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may result in lessening of competition in the UK.
Britain   Illumina
The Competition and Markets Authority (CMA), expressing concerns about the deal’s impact on the supply of specialist DNA sequencing systems in the UK, said the companies have until next week to respond to questions that it has raised.

Concerns over the Illumina-Pacific Biosciences deal include higher prices or lower quality products and less innovation in the market, the CMA said.